- Country: Norway
- Summary: Monitoring of the Drugs Adalimumab and Infliximab, Tests for Concentration in Serum to St. Olav Hospital H
- NOT Ref No: 108457447
- Deadline: 08 Nov 2024
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: NOK 3000000
- Notice Type: Tender
- Document Ref. No.: 2024-114201
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- The Department of Immunology and Transfusion Medicine at St. Olav's Hospital uses the above tests to measure the concentration of the drugs in human serum in patients with autoimmune inflammatory diseases (such as arthritis, Crohn's disease, ulcerative colitis, psoriasis and multiple sclerosis (MS)). The analyzes are included
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINMonitoring of the Drugs Adalimumab and Infliximab, Tests for Concentration in Serum to St. Olav Hospital H - Norway Tender
The SYKEHUSINNKJØP HF, a Government sector organization in Norway, has announced a new tender for Monitoring of the Drugs Adalimumab and Infliximab, Tests for Concentration in Serum to St. Olav Hospital H. This tender is published on NorwayTenders under NOT Ref No: 108457447 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2024-11-08.
The estimated tender value is NOK 3000000, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
